Changed Risks for GILEAD SCIENCES INC (GILD)

Here are risks that changed year over year. risks from the recent filings of GILEAD SCIENCES INC. Our algorithms work hard to highlight risks unique to this company.

Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions

Our success depends to a significant degree on our ability to defend our patents and other intellectual property rights both domestically and internationally We may not be able to obtain effective patents to protect our technologies from use by competitors

Yescarta, a chimeric antigen receptor (CAR) T cell therapy, represents a novel approach to cancer treatment that creates significant challenges for us, which may impact our ability to increase sales of Yescarta

We may face significant liability resulting from our products and such liability could materially reduce our earnings

Our inability to accurately predict demand for our products, uptake of new products or fluctuations in customer inventories makes it difficult for us to accurately forecast sales and may cause our forecasted revenues and earnings to fluctuate, which could adversely affect our financial results and stock price

If we fail to commercialize new products or expand the indications for existing products, our prospects for future revenues and our results of operations may be adversely affected

We have engaged in, and may in the future engage in, business acquisitions, licensing arrangements, strategic collaborations or disposal of our assets, which could cause us to incur significant expenses and could adversely affect our financial condition and results of operations

We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks and security breaches

We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption, which would adversely affect our prospects for future revenue growth and our results of operations

We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business